This Article  • Full text  • PDF  • Correction  • Original article  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (126)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in this journal  Topic Collections  • Quality of Life  • Statistics and Research Methods  • Schizophrenia  • Alert me on articles by topic

Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)

Peter B. Jones, MD, PhD; Thomas R. E. Barnes, MD, DSc; Linda Davies, MSc; Graham Dunn, PhD; Helen Lloyd, BA; Karen P. Hayhurst, MSc; Robin M. Murray, MD, DSc; Alison Markwick, BA; Shôn W. Lewis, MD

Arch Gen Psychiatry. 2006;63:1079-1087.

Context  Second-generation (atypical) antipsychotics (SGAs) are more expensive than first-generation (typical) antipsychotics (FGAs) but are perceived to be more effective, with fewer adverse effects, and preferable to patients. Most evidence comes from short-term efficacy trials of symptoms.

Objective  To test the hypothesis that in people with schizophrenia requiring a change in treatment, SGAs other than clozapine are associated with improved quality of life across 1 year compared with FGAs.

Design  A noncommercially funded, pragmatic, multisite, randomized controlled trial of antipsychotic drug classes, with blind assessments at 12, 26, and 56 weeks using intention-to-treat analysis.

Setting  Fourteen community psychiatric services in the English National Health Service.

Participants  Two hundred twenty-seven people aged 18 to 65 years with DSM-IV schizophrenia and related disorders assessed for medication review because of inadequate response or adverse effects.

Interventions  Randomized prescription of either FGAs or SGAs (other than clozapine), with the choice of individual drug made by the managing psychiatrist.

Main Outcome Measures  Quality of Life Scale scores, symptoms, adverse effects, participant satisfaction, and costs of care.

Results  The primary hypothesis of significant improvement in Quality of Life Scale scores during the year after commencement of SGAs vs FGAs was excluded. Participants in the FGA arm showed a trend toward greater improvements in Quality of Life Scale and symptom scores. Participants reported no clear preference for either drug group; costs were similar.

Conclusions  In people with schizophrenia whose medication is changed for clinical reasons, there is no disadvantage across 1 year in terms of quality of life, symptoms, or associated costs of care in using FGAs rather than nonclozapine SGAs. Neither inadequate power nor patterns of drug discontinuation accounted for the result.

Author Affiliations: Department of Psychiatry, University of Cambridge and Cambridgeshire and Peterborough Mental Health NHS Trust, Cambridge (Dr Jones); Division of Neurosciences and Mental Health, Imperial College, London (Dr Barnes and Ms Lloyd); Department of Psychiatry, University of Manchester, Manchester (Mss Davies, Hayhurst, and Markwick and Drs Dunn and Lewis); and Institute of Psychiatry, London (Dr Murray), England.

RELATED LETTERS

First- and Second-Generation Antipsychotics: Learning From CUtLASS and CATIE
Rajiv Tandon, William T. Carpenter, and John M. Davis
Arch Gen Psychiatry. 2007;64(8):977-978.
EXTRACT | FULL TEXT  

First- vs Second-Generation Antipsychotic Drugs in Schizophrenia
Chittaranjan Andrade and Saifuddin Kharawala
Arch Gen Psychiatry. 2007;64(8):978-979.
EXTRACT | FULL TEXT  

First- vs Second-Generation Antipsychotic Drugs in Schizophrenia—Reply
Peter B. Jones, Thomas R. E. Barnes, Peter Elton, Linda Davies, Graham Dunn, Helen Lloyd, Karen P. Hayhurst, Robin M. Murray, Alison Marwick, and Shôn Lewis
Arch Gen Psychiatry. 2007;64(8):979-980.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
Jeffrey A. Lieberman
Arch Gen Psychiatry. 2006;63(10):1069-1072.
EXTRACT | FULL TEXT  

Outcomes, Costs, and Policy Caution: A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Robert A. Rosenheck
Arch Gen Psychiatry. 2006;63(10):1074-1076.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Haloperidol versus chlorpromazine for treatment of schizophrenia
Leucht et al.
Schizophr Bull 2008;34:813-815.
FULL TEXT  

So careless of the single trial
Tyrer
Evid. Based Ment. Health 2008;11:65-66.
FULL TEXT  

Negative Symptoms in Schizophrenia: Avolition and Occam's Razor
Foussias and Remington
Schizophr Bull 2008;0:sbn094v1-sbn094.
ABSTRACT | FULL TEXT  

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
Swanson et al.
Br. J. Psychiatry 2008;193:37-43.
ABSTRACT | FULL TEXT  

Cognitive-behavioural therapy for severe mental disorders: back to the future?
Scott
Br. J. Psychiatry 2008;192:401-403.
ABSTRACT | FULL TEXT  

Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial
Garety et al.
Br. J. Psychiatry 2008;192:412-423.
ABSTRACT | FULL TEXT  

From the Editor's desk
Tyrer
Br. J. Psychiatry 2008;192:482-482.
FULL TEXT  

Bringing a research base to psychiatry
Shuchman and Hebert
CMAJ 2008;178:1257-1258.
FULL TEXT  

Etablir une base de recherche en psychiatrie
Shuchman and Hebert
CMAJ 2008;178:1259-1260.
FULL TEXT  

Introduction to the CATIE Special Section
Swartz
Psychiatr. Serv. 2008;59:497-499.
FULL TEXT  

What CATIE Found: Results From the Schizophrenia Trial
Swartz et al.
Psychiatr. Serv. 2008;59:500-506.
ABSTRACT | FULL TEXT  

Who Are the New Users of Antipsychotic Medications?
Domino and Swartz
Psychiatr. Serv. 2008;59:507-514.
ABSTRACT | FULL TEXT  

Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making
Rosenheck et al.
Psychiatr. Serv. 2008;59:515-520.
ABSTRACT | FULL TEXT  

Lessons to Take Home From CATIE
Carpenter and Buchanan
Psychiatr. Serv. 2008;59:523-525.
ABSTRACT | FULL TEXT  

What CATIE Did: Some Thoughts on Implications Deep and Wide
Owens
Psychiatr. Serv. 2008;59:530-533.
ABSTRACT | FULL TEXT  

Brief Reports: Psychiatric Opinion and Antipsychotic Selection in the Management of Schizophrenia
Arbuckle et al.
Psychiatr. Serv. 2008;59:561-565.
ABSTRACT | FULL TEXT  

Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine
Ohlsen et al.
J Psychopharmacol 2008;22:323-329.
ABSTRACT  

Cognitive Behavior Therapy for Schizophrenia: Effect Sizes, Clinical Models, and Methodological Rigor
Wykes et al.
Schizophr Bull 2008;34:523-537.
ABSTRACT | FULL TEXT  

Has Research Informed Us on the Practical Drug Treatment of Schizophrenia?
Davis and Leucht
Schizophr Bull 2008;34:403-405.
FULL TEXT  

Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials
Correll et al.
Schizophr Bull 2008;0:sbn018v2-sbn018.
ABSTRACT | FULL TEXT  

Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment
Parks et al.
Schizophr Bull 2008;0:sbn019v1-sbn019.
ABSTRACT | FULL TEXT  

Paliperidone for schizophrenia
Dolder et al.
Am J Health Syst Pharm 2008;65:403-413.
ABSTRACT | FULL TEXT  

Rethinking Antipsychotic Formulary Policy
Rosenheck et al.
Schizophr Bull 2008;34:375-380.
ABSTRACT | FULL TEXT  

Unanswered Questions in Schizophrenia Clinical Trials
Kane and Leucht
Schizophr Bull 2008;34:302-309.
FULL TEXT  

Methodological Issues in Current Antipsychotic Drug Trials
Leucht et al.
Schizophr Bull 2008;34:275-285.
ABSTRACT | FULL TEXT  

Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals
Stroup and Geddes
Schizophr Bull 2008;34:266-274.
ABSTRACT | FULL TEXT  

Clinical questions and uncertainty -- prolactin measurement in patients with schizophrenia and bipolar disorder
Walters and Jones
J Psychopharmacol 2008;22:82-89.
ABSTRACT  

CATIE and CUtLASS: can we handle the truth?
Lewis and Lieberman
Br. J. Psychiatry 2008;192:161-163.
ABSTRACT | FULL TEXT  

New-Onset Schizophrenia: Pharmacologic Treatment
Kane
Focus 2008;6:167-171.
ABSTRACT | FULL TEXT  

Neurocognition as a Treatment Target in Schizophrenia
Marder
Focus 2008;6:180-183.
ABSTRACT | FULL TEXT  

Bibliography Schizophrenia
Focus 2008;6:197-199.
FULL TEXT  

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
Kumra et al.
Schizophr Bull 2008;34:60-71.
ABSTRACT | FULL TEXT  

How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia
Owens
Adv. Psychiatr. Treat. 2008;14:17-28.
ABSTRACT | FULL TEXT  

A Systematic Review of the Soteria Paradigm for the Treatment of People Diagnosed With Schizophrenia
Calton et al.
Schizophr Bull 2008;34:181-192.
ABSTRACT | FULL TEXT  

Association Between Brain-Derived Neurotrophic Factor Val66Met Gene Polymorphism and Progressive Brain Volume Changes in Schizophrenia
Ho et al.
Am. J. Psychiatry 2007;164:1890-1899.
ABSTRACT | FULL TEXT  

Rapid tranquillisation in emergency psychiatric settings
Andrade
BMJ 2007;335:835-836.
FULL TEXT  

Experience of VA Psychiatrists With Pharmaceutical Detailing of Antipsychotic Medications
Sernyak and Rosenheck
Psychiatr. Serv. 2007;58:1292-1296.
ABSTRACT | FULL TEXT  

A Systematic Review of Mortality in Schizophrenia: Is the Differential Mortality Gap Worsening Over Time?
Saha et al.
Arch Gen Psychiatry 2007;64:1123-1131.
ABSTRACT | FULL TEXT  

Weighing In: Emergent Diabetes Mellitus and Second-Generation Antipsychotics
Dufresne
The Annals of Pharmacotherapy 2007;41:1725-1727.
ABSTRACT | FULL TEXT  

Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
Rosenheck
Br. J. Psychiatry 2007;191:238-245.
ABSTRACT | FULL TEXT  

Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects
Barbui et al.
Evid. Based Ment. Health 2007;10:74-74.
FULL TEXT  

First- and Second-Generation Antipsychotics: Learning From CUtLASS and CATIE
Tandon et al.
Arch Gen Psychiatry 2007;64:977-978.
FULL TEXT  

CUtLASS Confirms CATIE
Mintz and Kopelowicz
Arch Gen Psychiatry 2007;64:978-978.
FULL TEXT  

First- vs Second-Generation Antipsychotic Drugs in Schizophrenia Reply
Jones et al.
Arch Gen Psychiatry 2007;64:979-980.
FULL TEXT  

First- vs Second-Generation Antipsychotic Drugs in Schizophrenia
Andrade and Kharawala
Arch Gen Psychiatry 2007;64:978-979.
FULL TEXT  

Adverse effects of antipsychotics as outcome measures
Hamer and Haddad
Br. J. Psychiatry 2007;191:s64-s70.
ABSTRACT | FULL TEXT  

Measurement of long-term outcomes in observational and randomised controlled trials
Hodgson et al.
Br. J. Psychiatry 2007;191:s78-s84.
ABSTRACT | FULL TEXT  

Schizophrenia
Picchioni and Murray
BMJ 2007;335:91-95.
FULL TEXT  

Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy
Davies et al.
Br. J. Psychiatry 2007;191:14-22.
ABSTRACT | FULL TEXT  

Antipsychotics preferred by mental health professionals
Lepping
Psychiatr. Bull. 2007;31:272-272.
FULL TEXT  

Cognitive Improvement in Response to Antipsychotic Drugs: Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Heinrichs
Arch Gen Psychiatry 2007;64:631-632.
FULL TEXT  

Dominance of second-generation antipsychotics - time for reflection?
Underwood
Psychiatr. Bull. 2007;31:233-233.
FULL TEXT  

Differentiation in the Preonset Phases of Schizophrenia and Mood Disorders: Evidence in Support of a Bipolar Mania Prodrome
Correll et al.
Schizophr Bull 2007;0:sbm028v1-1.
ABSTRACT | FULL TEXT  

Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia
McCue
Evid. Based Ment. Health 2007;10:57-57.
FULL TEXT  

Editorial: Evidence-Based Therapeutics--Introducing the Cochrane Corner
Carpenter and Thaker
Schizophr Bull 2007;33:633-634.
FULL TEXT  

Furor Therapeuticus: Benjamin Rush and the Philadelphia Yellow Fever Epidemic of 1793
Eisenberg
Am. J. Psychiatry 2007;164:552-555.
FULL TEXT  

Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study
Swartz et al.
Am. J. Psychiatry 2007;164:428-436.
ABSTRACT | FULL TEXT  

Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden
Meltzer
Proc. Natl. Acad. Sci. USA 2007;104:3019-3020.
FULL TEXT  

Evidence-based psychopharmacology: an agenda for the future
Barbui and Cipriani
Evid. Based Ment. Health 2007;10:4-6.
FULL TEXT  

Outcomes similar with first- and second-generation antipsychotics
Seidlinger
Am J Health Syst Pharm 2006;63:2172-2175.
FULL TEXT  

The Distinction Between Antipsychotic Drug Classes Becomes More Blurred
JWatch Psychiatry 2006;2006:2-2.
FULL TEXT  

Newer antipsychotic drugs are no better than older ones, study finds.
Tanne
BMJ 2006;333:771-771.
FULL TEXT  

Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Lieberman
Arch Gen Psychiatry 2006;63:1069-1072.
FULL TEXT  

Outcomes, Costs, and Policy Caution: A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Rosenheck
Arch Gen Psychiatry 2006;63:1074-1076.
FULL TEXT  

Bibliography PSYCHOPHARMACOLOGY
Focus 2006;4:512.
FULL TEXT  

Abstracts PSYCHOPHARMACOLOGY
Focus 2006;4:515.
FULL TEXT